Nexalin Technology (NXL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$217,155.00

Revenue (quarter)

$12,161.00

Revenue growth (year over year)

−82.77%

Gross profit (trailing twelve months)

$187,097.00

Gross margin

86.16%

Net income (trailing twelve months)

−$9.0M

Net income (quarter)

−$2.2M

Net income growth (year over year)

−41.63%

Net margin

−4139.38%

Return on equity

−240.25%

EPS (trailing twelve months)

−$6.55

Book value per share

$2.07

P/E (trailing twelve months)

—

Price to book

1.65

Debt to assets

49.42%

Payout ratio

—

Dividend yield

—

Company profile

Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.

• Is Nexalin Technology (NXL) profitable?

  No. Nexalin Technology reported a net loss of $9.0M over the trailing twelve months.

• How much revenue does Nexalin Technology (NXL) make?

  Nexalin Technology generated $217,155.00 in revenue over the trailing twelve months, down 82.77% year over year.

• How do I buy stock in Nexalin Technology (NXL)?

  NXL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.